Mr. Sanay joined Altimmune in March 2026 as Vice President, Investor Relations. He is an accomplished finance leader with 15 years of experience in investor relations.
Prior to joining Altimmune, he served as Vice President of Investor Relations at Novavax, where he engaged with investors and analysts and communicated the company’s value proposition, investment thesis, financial performance, and long-term strategy. Previously, he served as Head of Investor Relations at Harmony Biosciences (Nasdaq: HRMY), a CNS focused biotechnology company and Director of Investor Relations at Viatris (Nasdaq: VTRS), a global pharmaceutical company. Before transitioning to the healthcare industry, he began his career in financial services and worked at CIT Group and The Hartford Insurance Group.
Mr. Sanay holds a bachelor’s degree in Economics and Finance from the University of Hartford and is a CFA charterholder.
